Next earnings date: 18 Aug 2025
LAVA Therapeutics N.V. – NASDAQ:LVTX
LAVA Therapeutics N.V. stock price today
$1.53
+0.53
+54.02%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 6 hours
LAVA Therapeutics N.V. stock price monthly change
-46.90%
month
LAVA Therapeutics N.V. stock price quarterly change
-46.90%
quarter
LAVA Therapeutics N.V. stock price yearly change
-35.94%
year
LAVA Therapeutics N.V. key metrics
Market Cap | 26.29M |
Enterprise value | N/A |
P/E | -1.47 |
EV/Sales | -1.28 |
EV/EBITDA | 0.74 |
Price/Sales | 2.01 |
Price/Book | 0.39 |
PEG ratio | N/A |
EPS | -1.08 |
Revenue | 12.53M |
EBITDA | -28.85M |
Income | -28.58M |
Revenue Q/Q | 471.24% |
Revenue Y/Y | -36.01% |
Profit margin | -182.04% |
Oper. margin | -188.6% |
Gross margin | 0% |
EBIT margin | -188.6% |
EBITDA margin | -230.17% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeLAVA Therapeutics N.V. stock price history
LAVA Therapeutics N.V. stock forecast
LAVA Therapeutics N.V. financial statements
| Jun 2023 | 5.13M | -12.7M | -247.13% |
|---|---|---|---|
| Sep 2023 | 53K | -8.83M | -16671.7% |
| Dec 2023 | 352.99K | -6.49M | -1840.8% |
| Mar 2024 | 6.99M | -553K | -7.91% |
| Dec 2023 | 352.99K | -6.49M | -1840.8% |
|---|---|---|---|
| Mar 2024 | 6.99M | -553K | -7.91% |
| Sep 2025 | 8.69M | -11.87M | -136.6% |
| Dec 2025 | 9.01M | -9.42M | -104.57% |
Analysts Price target
Financials & Ratios estimates
| 2024-12-10 | -0.33 | -0.46 |
|---|
| Jun 2023 | 122541000 | 58.64M | 47.86% |
|---|---|---|---|
| Sep 2023 | 111020000 | 56.42M | 50.82% |
| Dec 2023 | 101710000 | 50.53M | 49.68% |
| Mar 2024 | 99079000 | 48.41M | 48.86% |
| Jun 2023 | -13.06M | 224K | -157K |
|---|---|---|---|
| Sep 2023 | -7.45M | -16.84M | -137K |
| Dec 2023 | -10.12M | -8.68M | -180K |
| Mar 2024 | -1.12M | 718K | 0 |
LAVA Therapeutics N.V. alternative data
| Aug 2023 | 69 |
|---|---|
| Sep 2023 | 69 |
| Oct 2023 | 69 |
| Nov 2023 | 69 |
| Dec 2023 | 69 |
| Jan 2024 | 69 |
| Feb 2024 | 69 |
| Mar 2024 | 69 |
| Apr 2024 | 69 |
| May 2024 | 37 |
| Jun 2024 | 37 |
| Jul 2024 | 37 |
LAVA Therapeutics N.V. other data
3.55%
-34.44%
of LVTX is owned by hedge funds
919.25K
-6.58M
shares is hold by hedge funds
-
What's the price of LAVA Therapeutics N.V. stock today?
One share of LAVA Therapeutics N.V. stock can currently be purchased for approximately $1.53.
-
When is LAVA Therapeutics N.V.'s next earnings date?
LAVA Therapeutics N.V. is estimated to report earnings on Monday, 18 Aug 2025.
-
Does LAVA Therapeutics N.V. pay dividends?
No, LAVA Therapeutics N.V. does not pay dividends.
-
How much money does LAVA Therapeutics N.V. make?
LAVA Therapeutics N.V. has a market capitalization of 26.29M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 65.09% to 6.77M US dollars. LAVA Therapeutics N.V. made a loss 41.97M US dollars in net income (profit) last year or -$0.46 on an earnings per share basis.
-
What is LAVA Therapeutics N.V.'s stock symbol?
LAVA Therapeutics N.V. is traded on the NASDAQ under the ticker symbol "LVTX".
-
What is LAVA Therapeutics N.V.'s primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of LAVA Therapeutics N.V.?
Shares of LAVA Therapeutics N.V. can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does LAVA Therapeutics N.V. have?
As Jul 2024, LAVA Therapeutics N.V. employs 37 workers, which is 46% less then previous quarter.
-
When LAVA Therapeutics N.V. went public?
LAVA Therapeutics N.V. is publicly traded company for more then 4 years since IPO on 26 Mar 2021.
-
What is LAVA Therapeutics N.V.'s official website?
The official website for LAVA Therapeutics N.V. is lavatherapeutics.com.
-
How can i contact LAVA Therapeutics N.V.?
LAVA Therapeutics N.V. can be reached via phone at +31 6 30003035.
LAVA Therapeutics N.V. company profile:
LAVA Therapeutics N.V.
lavatherapeutics.comExchange:
NASDAQ
Full time employees:
37
Industry:
Biotechnology
Sector:
Healthcare
LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company, through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-051, which is in Phase 1/2a clinical trial for blood cancers, including chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia; and LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is also developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 and LAVA-1278, which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use. The company was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.
Yalelaan 60
Utrecht, 3584 CM
Utrecht, 3584 CM
CIK: 0001840748
ISIN: NL0015000AG6
CUSIP: N51517105
